Euro vs US Dollar

Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

Registrieren

OCX Oncocyte Corporation

2,03

0,00 (0,00%)

Vor Marktöffnung

Zuletzt aktualisiert: 13:00:08

Verzögert um 15 Minuten

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Oncocyte (NASDAQ:OCX)
Historical Stock Chart
Von Dez 2024 bis Jan 2025

Click Here for more Oncocyte Charts.

Oncocyte (NASDAQ:OCX)
Historical Stock Chart
Von Jan 2024 bis Jan 2025

Click Here for more Oncocyte Charts.

News Oncocyte Corporation

Form 8-K - Current report
Mittwoch 8 Januar 2025 (3 Wochen vor) • Edgar (US Regulatory)

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer
Mittwoch 8 Januar 2025 (3 Wochen vor) • GlobeNewswire Inc.

Oncocyte Expands Market Opportunity for VitaGraft™ Kidney
Montag 6 Januar 2025 (3 Wochen vor) • GlobeNewswire Inc.

Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings
Montag 9 Dezember 2024 (2 Monate vor) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Montag 9 Dezember 2024 (2 Monate vor) • Edgar (US Regulatory)

Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study
Mittwoch 4 Dezember 2024 (2 Monate vor) • GlobeNewswire Inc.

Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms
Montag 2 Dezember 2024 (2 Monate vor) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Dienstag 12 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 8-K - Current report
Dienstag 12 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025
Dienstag 12 November 2024 (2 Monate vor) • GlobeNewswire Inc.

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12
Mittwoch 6 November 2024 (3 Monate vor) • GlobeNewswire Inc.

Form 424B3 - Prospectus [Rule 424(b)(3)]
Dienstag 22 Oktober 2024 (3 Monate vor) • Edgar (US Regulatory)

Weitere Oncocyte Corporation News-Artikel

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen